Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
MAPS reports results from a randomized, blinded Phase 3 trial of MDMA-assisted therapy for severe, chronic PTSD (90 people, average 14 years of PTSD). After three MDMA-assisted therapy sessions, 67% of treated participants no longer met the study's PTSD diagnosis and 88% had a clinically meaningful symptom drop, compared with…
This paper is a protocol for a planned systematic review and meta-analysis. The authors will collect and combine studies that test group-based treatments for people with PTSD or people referred to PTSD group treatment. They plan to look not only at whether group treatments reduce PTSD symptoms, but also at…
